CD19 and B-cell chronic lymphocytic leukemia: Surprisingly, anti-CD19 CAR-T cell treatment has not reached the expected outcomes in CLL, with an average complete remission rate of ~30%, significantly lower compared to that obtained in acute lymphoblastic leukemia and diffuse large B cell lymphoma [155,156,157,158].